+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
All Ages
All Genders
ID06651281

Long-term Extension Study Evaluating Safety and Tolerability of Tulisokibart in Adults with Crohns Disease or Ulcerative Colitis

Led by Merck Sharp & Dohme LLC · Updated on 2026-11-03

1380

Participants Needed

37

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying tulisokibart MK-7240, a medicine designed to treat active moderate to severe Crohns disease CD and ulcerative colitis UC. This is a Phase 3 extension study for people who previously received tulisokibart in earlier parent studies. The goal is to learn about the long-term safety and how well people tolerate tulisokibart over time. Participants in this study receive tulisokibart as a subcutaneous injection in different dose regimens, including low and high doses, some of which are blinded to the participant. The study compares these dosing regimens in parallel groups to monitor effects over a long period. During the study, participants will be monitored up to approximately 378 weeks to track any adverse events or reasons for stopping the study treatment. Researchers will collect safety data and assess tolerability while participants continue receiving the study drug. The total duration and follow-up extend for several years to understand long-term outcomes.

CONDITIONS

Brief Title

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here